INNATE PHARMA ANNOUNCES ITS FINANCIAL CALENDAR FOR 2017
Marseille, France, January 4, 2017
Innate Pharma SA (the “Company” – Euronext Paris: FR0010331421 – IPH) today announces its financial calendar for 2017, which is set as follows:
- March 7, 2017: Publication of 2016 financial statements, with management comments.
The 2016 Reference Document and Financial Report (included in the Reference Document) will be released during the second quarter of 2017. - May 15, 2017: Publication of revenue for 1Q2017, with management comments.
- June 23, 2017: Annual shareholders meeting in Marseille.
- September 18, 2017: Publication of financial statements as of June 30, 2017, with management comments.
- November 15, 2017: Publication of revenue for 3Q2017, with management comments.
All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company’s website in the Investors’ section (http://www.innate-pharma.com/en/investors).
About Innate Pharma:
Innate Pharma S.A. is a clinical-stage biotechnology company with a focus on discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients.
Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body’s immune system to recognize and kill cancer cells.
The Company’s aim is to become a commercial stage biopharmaceutical company in the area of immunotherapy and focused on serious unmet medical needs in cancer. Innate Pharma has pioneered the discovery and development of checkpoint inhibitors to activate the innate immune system. Innate Pharma’s innovative approach has resulted in three first-in-class, clinical-stage antibodies targeting natural killer cell receptors that may address a broad range of solid and hematological cancer indications as well as additional preclinical product candidates and technologies. Targeting receptors involved in innate immunity also creates opportunities for the Company to develop therapies for inflammatory diseases.
The Company’s expertise and understanding of natural killer cell biology have enabled it to enter into major alliances with leaders in the biopharmaceutical industry including AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi.
Based in Marseille, France, Innate Pharma has more than 150 employees and is listed on Euronext Paris.
Learn more about Innate Pharma at www.innate-pharma.com.
Practical Information about Innate Pharma shares:
| ISIN code Ticker code |
FR0010331421 IPH |
Disclaimer:
This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma’s website.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
For additional information, please contact:
| Innate Pharma
Laure-Hélène Mercier Tel.: +33 (0)4 30 30 30 87
|
International Media and Investor Relations Consilium Strategic Communications Mary-Jane Elliott / Sue Stuart / Tel.: +44 (0)20 3709 5700 |
| ATCG Press (France)
Marie Puvieux Mob: +33 (0)6 10 54 36 72
|
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/872adac8-c565-47f8-a760-b94baaec0321
